Prognostic value of estrogen receptor status can be improved by combined evaluation of p53, Bcl2 and PgR expression: An immunohistochemical study on breast carcinoma with long-term follow-up

摘要: Steroid receptor analysis is the only widely accepted prognostic/predictive marker in breast cancer (BC) treatment. In present study we evaluated prognostic role of ER/PgR with p53 and Bcl2, a series 277 BC (153 pN1/2, 122 pNO, 2 pNx) long-term follow-up (67 months for DFS, 75 OS). Our results, besides confirming usefulness ER immunohistochemical expression as marker, showed that PgR alone had borderline/not significant value whole (p=0.08 DFS p=0.09 OS), while to be N+ cases (p=0.02 p=0.03 value, however, was not independent at multivariate analysis. By combining PgR, ER/p53 ER/Bcl2 phenotypes better discriminant than phenotype. The ER+/p53+ phenotype higher risk relapse/death compared ER+/p53- Conversely ER-/p53+ most unfavourable prognosis. Similar results could observed concerning phenotypes. combined evaluation weakly enhanced power status alone. On contrary, ER/Bcl2, improved this capability allowed separation positive negative into subgroups different